The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

Lancet

Volumn 368, Issue 9548, 2006, Pages 1696-1705

  Drucker, Daniel J ^a   Nauck, Michael A ^b  

^a MOUNT SINAI HOSPITAL   (Canada)

^b DIABETESZENTRUM BAD LAUTERBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; DENAGLIPTIN; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EXENDIN 4; GLIMEPIRIDE; GLITAZONE DERIVATIVE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; HEMOGLOBIN A1C; HORMONE RECEPTOR STIMULATING AGENT; INCRETIN; INSULIN; INSULIN GLARGINE; LIRAGLUTIDE; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; VILDAGLIPTIN;

APPETITE; CLINICAL TRIAL; DIARRHEA; DIET RESTRICTION; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG SAFETY; FOOD INTAKE; GASTROINTESTINAL SYMPTOM; GLUCAGON RELEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPOGLYCEMIA; INJECTION; INTESTINE; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; POSTPRANDIAL STATE; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; STOMACH EMPTYING; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

ADAMANTANE; ADENOSINE DEAMINASE; ANTIGENS, CD26; CLINICAL TRIALS; DIABETES MELLITUS, TYPE 2; DRUG ADMINISTRATION SCHEDULE; GLUCAGON-LIKE PEPTIDE 1; GLYCOPROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; PEPTIDES; PYRAZINES; RECEPTORS, GLUCAGON; TRIAZOLES; VENOMS;

EID: 33846006173     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(06)69705-5     Document Type: Review

References (109)

1. Elrick H., Stimmler L., Hlad C., and Arai Y. Plasma insulin response to oral and intravenous glucose administration. J Clin Endocrinol Metab 24 (1964) 1076-1082
2. Dupré J., Ross S., Watson D., and Brown J. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. J Clin Endocrinol Metab 37 (1973) 826-828
3. Ørskov C., Wettergren A., and Holst J. Biological effects and metabolic rates of glucagonlike peptide-1 7-36 amide and glucagonlike peptide-1 7-37 in healthy subjects are indistinguishable. Diabetes 42 (1993) 658-661
4. Marguet D., Baggio L., Kobayashi T., et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 97 (2000) 6874-6879
5. Deacon C., Nauck M., Toft-Nielsen M., Pridal L., Willms B., and Host J. Both subcutaneously and intravenously administered glucagon-like peptide 1 are rapidly degraded from the NH2-terminus in type 2-diabetic patients and in healthy subjects. Diabetes 44 (1995) 1126-1131
6. Drucker D., Philippe J., Mojsov S., Chick W., and Habener J. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84 (1987) 3434-3438
7. Drucker D. The biology of incretin hormones. Cell Metab 3 (2006) 153-165
8. Li Y., Hansotia T., Yusta B., Ris F., Halban P., and Drucker D. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 278 (2003) 471-478
9. Farilla L., Bulotta A., Hirshberg B., et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 144 (2003) 5149-5158
10. Burcelin R., Da Costa A., Drucker D., and Thorens B. Glucose competence of the hepatoportal vein sensor requires the presence of an activated glucagon-like peptide-1 receptor. Diabetes 50 (2001) 1720-1728
11. Nauck M., Heimesaat M., Behle K., et al. Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab 87 (2002) 1239-1246
12. Miyawaki K., Yamada Y., Yano H., et al. Glucose intolerance caused by a defect in the entero-insular axis: A study in gastric inhibitory polypeptide receptor knockout mice. Proc Natl Acad Sci USA 96 (1999) 14843-14847
13. Scrocchi L., Brown T., MaClusky N., et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 2 (1996) 1254-1258
14. Schirra J., Sturm K., Leicht P., Arnold R., Göke B., and Katschinski M. Exendin (9-39)amide is an antagonist of glucagon-like peptide-1 (7-36) amide in humans. J Clin Invest 101 (1998) 1421-1430
15. Nauck M., Stöckmann F., Ebert R., and Creutzfeldt W. Reduced incretin effect in type 2 (non-insulin-dependent) diabetes. Diabetologia 29 (1986) 46-54
16. Nauck M., Heimesaat M., Ørskov C., Holst J., Ebert R., and Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus. J Clin Invest 91 (1993) 301-307
17. Toft-Nielsen M., Damholt M., Madsbad S., et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 86 (2001) 3717-3723
18. Nauck M., Kleine N., Ørskov C., Holst J., Willms B., and Creutzfeldt W. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 36 (1993) 741-744
19. Toft-Nielsen M., Madsbad S., and Holst J. Determinants of the effectiveness of glucagon-like peptide-1 in type 2 diabetes. J Clin Endocrinol Metab 86 (2001) 3853-3860
20. Nauck M., and Meier J. Glucagon-like peptide 1 (GLP-1) and its derivatives in the treatment of diabetes. Regul Pept 124 suppl (2005) 135-148
21. Willms B., Werner J., Holst J., Ørskov C., Creutzfeldt W., and Nauck M. Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients. J Clin Endocrinol Metab 81 (1996) 327-332
22. Zander M., Madsbad S., Madsen J., and Holst J. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 359 (2002) 824-830
23. Meier J., Weyhe D., Michaely M., et al. Intravenous glucagon-like peptide 1 normalizes blood glucose after major surgery in patients with type 2 diabetes. Crit Care Med 32 (2004) 848-851
24. Nauck M., Walberg J., Vethacke A., et al. Blood glucose control in healthy subject and patients receiving intravenous glucose infusion or total parenteral nutrition using glucagon-like peptide 1. Regul Pept 118 (2004) 89-97
25. DeFronzo R., Ratner R., Han J., Kim D., Fineman M., and Baron A. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 28 (2005) 1092-1100
26. Buse J., Henry R., Han J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2628-2635
27. Kendall D., Riddle M., Rosenstock J., et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 28 (2005) 1083-1091
28. Zinman B., Hoogwerf B., Garcia S., et al. Safety and efficacy of exenatide in patients with type 2 diabetes mellitus using thiazolidindiones with or without metformin. Diabetes 55 suppl 1 (2006) 28 (abstr 117-OR)
29. Heine R., Van Gaal L., Johns D., Mihm M., Widel M., and Brodows R. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 143 (2005) 559-569
30. Kim D., MacConnell L., Zhuang D., et al. Safety and efficacy of a once-weekly, long-acting release formulation of exenatide over 15 weeks in patients with type 2 diabetes. Diabetes 55 suppl 1 (2006) 116 (abstr 487-P)
31. Madsbad S., Schmitz O., Ranstam J., Jakobsen G., and Matthews D. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12-week, double-blind, randomized, controlled trial. Diabetes Care 27 (2004) 1335-1342
32. Nauck M., Hompesch M., Filipicazak R., Le T., Zdravkovic M., and Glumprecht J. Five weeks of treatment with the GLP-1 analogue liraglutadide improves glycaemic control and lowers body weight in subjects with type 2 diabetes. Exp Clin Endocrinol Diabetes 114 (2006) 417-423
33. Vilsbøll T., Zdravkovic M., Le-Thi T., et al. Liraglutide significantly improves glycemic control, and lowers body weight without risk of either major or minor hypoglycemic episodes in subjects with type 2 diabetes. Diabetes 55 suppl 1 (2006) 27-28 (abstr 115-OR)
34. Åhren B., Gomis R., Standl E., Mills D., and Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care 27 (2004) 2874-2880
35. Pratley R., Jauffret-Kamel S., Galbreath E., and Holmes D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes. Horm Metab Res 38 (2006) 423-428
36. 1c during one-year treatment with vildagliptin in patients with type 2 diabetes (T2DM). Diabetes 55 suppl 1 (2006) 29 (abstr 120-OR)
37. 1c but without weight gain in drug-naive patients with type 2 diabetes (T2DM). Diabetes 55 suppl 1 (2006) 133 (abstr 557-P)
38. Garber A., Camisasca R., Ehrsam E., Collober-Maugeais C., Rochotte E., and Lebeaut A. Vildagliptin added to metformin improves glycemic control and may mitigate metformin-induced GI side effects in patients with type 2 diabetes (T2DM). Diabetes 55 suppl 1 (2006) 29 (abstr 121-OR)
39. Raz I., Hanefeld M., Xu L., Caria C., Williams-Herman D., and Khatami H. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia 49 (2006) 2564-2571
40. Aschner P., Kipnes M., Lunceford J., Mickel C., Davies M., and Williams-Herman D. Sitagliptin monotherapy improved glycemic control in the fasting and postprandial states and beta-cell function after 24 weeks in patients with type 2 diabetes (T2DM). Diabetes 55 suppl 1 (2006) 462 (abstr 1995-PO)
41. Karasik A., Charbonnell B., Liu J., Wu M., Meehan A., and Meininger G. Sitagliptin added to ongoing metformin therapy enhanced glycemic control and beta-cell function in patients with type 2 diabetes. Diabetes 55 suppl 1 (2006) 119 -20 (abstr 501-P)
42. Rosenstock J., Brazg R., Andryuk P., McCrary Sisk C., Lu K., and Stein P. Addition of sitagliptin to pioglitazone improved glycemic control with neutral weight effect over 24 weeks in inadequately controlled type 2 diabetes (T2DM). Diabetes 55 suppl 1 (2006) 132 -33 (abstr 556-P)
43. Eng J., Kleinman W., Singh L., Singh G., and Raufman J. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 267 (1992) 7402-7405
44. Chen Y., and Drucker D. Tissue-specific expression of unique mRNAs that encode proglucagon-derived peptides or exendin 4 in the lizard. J Biol Chem 272 (1997) 4108-4115
45. Kolterman O., Buse J., Fineman M., et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 3082-3089
46. Juhl C., Hollingdal M., Sturis J., et al. Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. Diabetes 51 (2002) 424-429
47. Åhren B., Landin-Olsson M., Jansson P., Svensson M., Holmes D., and Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89 (2004) 2078-2084
48. Quddusi S., Vahl T., Hanson K., Prigeon R., and D'Alessio D. Differential effects of acute and extended infusions of glucagon-like peptide-1 on first- and second-phase insulin secretion in diabetic and nondiabetic humans. Diabetes Care 26 (2003) 791-798
49. Fehse F., Trautmann M., Holst J., et al. Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 90 (2005) 5991-5997
50. Polonsky K., Given B., Hirsch L., et al. Abnormal patterns of insulin secretion in non-insulin-dependent diabetes mellitus. N Engl J Med 318 (1988) 1231-1239
51. Rachman J., Gribble F., Levy J., and Turner R. Near-normalization of diurnal glucose concentrations by continuous administration of glucagon-like peptide 1 (GLP-1) in subjects with NIDDM. Diabetologia 40 (1997) 205-211
52. Gerich J. Abnormal glucagon secretion in type 2 (noninsulin-dependent) diabetes mellitus: causes and consequences. In: Creutzfeldt W., and Lefèbvre P. (Eds). Diabetes mellitus: pathophysiology and therapy (1989), Springer Verlag, Berlin, Heidelberg 127-133
53. Degn K., Brock B., Juhl C., et al. Effect of intravenous infusion of exenatide (synthetic exendin-4) on glucose-dependent insulin secretion and counterregulation during hypoglycemia. Diabetes 53 (2004) 2397-2403
54. Nauck M., El-Ouaghlidi A., Hompesch M., Jacobsen J., and Elbrønd B. No impairment of hypoglycemia counterregulation via glucagon with NN2211, a GLP-1 derivative, in subjects with type 2 diabetes. Diabetes 52 suppl 1 (2003) 128 (abstr 550-P)
55. Alarcon C., Wicksteed B., and Rhodes C. Exendin 4 controls insulin production in rat islet beta cells predominantly by potentiation of glucose-stimulated proinsulin biosynthesis at the translational level. Diabetologia (2006) [In press] Published online October 20, 2006
56. Rahier J., Goebbels R., and Henquin J. Cellular composition of the human diabetic pancreas. Diabetologia 24 (1983) 366-371
57. Butler A., Janson J., Bonner-Weir S., Ritzel R., Rizza R., and Butler P. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 52 (2003) 102-110
58. Buteau J., Foisy S., Rhodes C., Carpenter L., Biden T., and Prentki M. Protein kinase Czeta activation mediates glucagon-like peptide-1-induced pancreatic beta-cell proliferation. Diabetes 50 (2001) 2237-2243
59. Xu G., Stoffers D., Habener J., and Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48 (1999) 2270-2276
60. Rolin B., Larsen M., Gotfredsen C., et al. The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice. Am J Physiol (Endocrinol Metab) 283 (2002) 745-752
61. Mu J., Woods J., Zhou Y., et al. Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic {beta}-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55 (2006) 1695-1704
62. Abraham E., Leech C., Lin J., Zulewski H., and Habener J. Insulinotropic hormone glucagon-like peptide-1 differentiation of human pancreatic islet-derived progenitor cells into insulin-producing cells. Endocrinology 143 (2002) 3152-3161
63. Hui H., Nourparvar A., Zhao X., and Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 144 (2003) 1444-1455
64. Li Y., Cao X., Li L., Brubaker P., Edlund H., and Drucker D. ß-cell PDX1 expression is essential for the glucoregulatory, proliferative, and cytoprotective actions of glucagon-like peptide-1. Diabetes 54 (2005) 482-491
65. Bregenholdt S., Moldrup A., B. Knudsen L., and Petersen J. The GLP-1 derivative NN2211 inhibits cytokine-induced apoptosis in primary rat ß-cells. Diabetes 50 suppl 1 (2001) 31 (abstr)
66. Pospisilik J., Martin J., Doty T., et al. Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats. Diabetes 52 (2003) 741-750
67. Phillips W., Salman U., McMahan C., and Schwartz J. Accelerated gastric emptying in hypertensive subjects. J Nucl Med 38 (1997) 207-211
68. Wettergren A., Schjoldager B., Mortensen P., Myhre J., Christiansen J., and Holst J. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38 (1993) 665-673
69. Kolterman O., Kim D., Shen L., et al. Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes melllitus. Am Health Syst Pharm 62 (2005) 173-181
70. Dardik B., Valentin M., Schwartzkopf C., et al. NVP-LAF237, a dipeptidyl peptidase IV inhibitor, improves glucose tolerance and delays gastric emptying in obese insulin resistant Cynomolgus monkeys. Diabetes 52 suppl 1 (2003) 322 (abstr 1292-P)
71. El-Ouaghlidi A., Rehring E., Schweizer A., Holmes D., and Nauck M. The dipeptidyl peptidase IV inhibitor LAF237 does not accentuate reactive hypoglyaemia caused by the sulfonylurea glibenclamide administered before an oral glucose load in healthy subjects. Diabetes 52 suppl 1 (2003) 118 (abstr 507-P)
72. Colditz G., Willett W., Rotnitzky A., and Manson J. Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med 122 (1995) 481-486
73. Flint A., Raben A., Astrup A., and Holst J. Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101 (1998) 515-520
74. Szayna M., Doyle M., Betkey J., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 141 (2000) 1936-1941
75. Hansen B., Bjenning C., and Bjerrre Knudsen L. Sustained appetite suppression and weight loss in obese rhesus monkeys treated with a long-acting GLP-1 derivative, NN2211. Diabetologia 44 suppl 1 (2001) 196 (abstr)
76. Nielsen L., and Baron A. Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 diabetes. Curr Opin Investig Drugs 4 (2003) 401-405
77. Nielsen L., Young A., and Parkes D. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 117 (2004) 77-88
78. Fineman M., Shen L., Smitzi J., et al. Unique study design: Evaluation of the effect of dose titration on dose-limiting nausea. Clin Pharmacol Ther 71 (2002) 19 (abstr)
79. Fineman M., Shen L., Taylor K., Kim D., and Baron A. Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes. Diabetes Metab Res Rev 20 (2004) 411-417
80. Riddle M., Henry R., Poon T., et al. Exenatide elicits sustained glycaemic control and progressive reduction of body weight in patients with type 2 diabetes inadequately controlled by sulphonylureas with or without metformin. Diabetes Metab Res Rev 22 (2006) 483-491
81. Knudsen L., Nielsen P., Huusfeldt P., et al. Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration. J Med Chem 43 (2000) 1664-1669
82. Bjerre Knudsen L., Møller Knudsen S., Wilken M., et al. Plasma protein binding of NN2211, a long-acting derivative of GLP-1, is important for its efficacy. Diabetes 52 suppl 1 (2005) 321-322
83. Agersø H., Jensen L., Elbrond B., Rolan P., and Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 45 (2002) 195-202
84. Elbrønd B., Jakobsen G., Larsen S., et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 25 (2002) 1398-1404
85. Saad M., An B., Santiago O., and on behalf of the 2072 study group. The effect of NN2211, a long-acting GLP-1 derivative, on glycemic control and body weight in obese patients with type 2 diabetes. Diabetologia 45 suppl 2 (2002) 44 (abstr)
86. Gedulin B., Smith P., Prickett K., et al. Dose-response for glycaemic and metabolic changes 28 days after single injection of long-acting release exenatide in diabetic fatty Zucker rats. Diabetologia 48 (2005) 1380-1385
87. Kim J., Baggio L., Bridon D., et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 52 (2003) 751-759
88. Baggio L., Huang Q., Brown T., and Drucker D. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 53 (2004) 2492-2500
89. Mentlein R., Gallwitz B., and Schmidt W. Dipeptidyl-peptidase IV hydrolyses gastric inhibitory polypeptide, glucagon-like peptide-1(7-36)amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214 (1993) 829-835
90. Kieffer T., McIntosh C., and Pederson R. Degradation of glucose-dependent insulinotropic polypeptide and truncated glucagon-like peptide 1 in vitro and in vivo by dipeptidyl peptidase IV. Endocrinology 136 (1995) 3585-3596
91. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 85 (1999) 9-24
92. De Meester I., Durinx C., Bal G., et al. Natural substrates of dipeptidyl peptidase IV. Adv Exp Med Biol 477 (2000) 67-87
93. De Meester I., Lambeir A., Proost P., and Scharpe S. Dipeptidyl peptidase IV substrates: an update on in vitro peptide hydrolysis by human DPPIV. Adv Exp Med Biol 524 (2003) 3-17
94. Deacon C., Nauck M., Meier J., Hücking K., and Holst J. Degradation of endogenous and exogenous gastric inhibitory polypeptide in healthy and in type 2 diabetic subjects as revealed using a new assay for the intact peptide. J Clin Endocrinol Metab 85 (2000) 3575-3581
95. Deacon C., Johnsen A., and Holst J. Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. J Clin Endocrinol Metab 80 (1995) 952-957
96. Deacon C. Therapeutic strategies based on glucagon-like peptide 1. Diabetes 53 (2004) 2181-2189
97. Herman G., Stevens C., Van Dyck K., et al. Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses. Clin Pharmacol Ther 78 (2005) 675-688
98. Nauck M., and El-Ouaghlidi A. The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1. Diabetologia 48 (2005) 608-611
99. Villhauer E., Brinkman J., Naderi G., et al. 1-[[(3-hydroxy-1-adamantyl)amino]acetyl]-2-cyano-(S)-pyrrolidine: a potent, selective, and orally bioavailable dipeptidyl peptidase IV inhibitor with antihyperglycemic properties. J Med Chem 46 (2003) 2774-2789
100. Åhren B., Pacini G., Foley J., and Schweizer A. Improved meal-related beta-cell function and insulin sensitivity by the dipeptidyl peptidase-IV inhibitor vildagliptin in metformin-treated patients with type 2 diabetes over 1 year. Diabetes Care 28 (2005) 1936-1940
101. Augeri D., Robl J., Betebenner D., et al. Discovery and preclinical profile of saxagliptin (BMS-477118): a highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48 (2005) 5025-5037
102. Demuth H., McIntosh C., and Pederson R. Type 2 diabetes-therapy with dipeptidyl peptidase IV inhibitors. Biochim Biophys Acta 1751 (2005) 33-44
103. Scott R., Herman G., Zhao P., Chen X., Wu M., and Stein P. Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D). Diabetes 54 suppl 1 (2005) 10 -11 (abstr 41-OR)
104. Hanefeld M., Herman G., Mickel C., et al. Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetologia 48 suppl 1 (2005) 287 -88 (abstr 791)
105. Brazg R., Thomas K., Zhao P., Xu L., Chen X., and Stein P. Effect of adding MK-0431 to ongoing metformin therapy in type 2 diabetic patients who have inadequate glycemic control on metformin. Diabetes 54 suppl 1 (2005) 3 (abstr)
106. Lankas G., Leiting B., Roy R., et al. Dipeptidyl peptidase IV inhibiton for the treatment of type 2 diabetes: potential importance of selectivity over dipeptidyl peptidase 8 and 9. Diabetes 54 (2004) 2988-2994
107. Meier J., Gallwitz B., Salmen S., et al. Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab 88 (2003) 2719-2725
108. Kolterman O., Gottlieb A., Prickett K., Gaines E., and Young A. Dose-response for inhibition of glucagon secretion and gastric emptying by synthetic exendin-4 (AC2993) in subjects with type 2 diabetes. Diabetes 49 suppl 1 (2000) 114 (abstr)
109. Nikolaidis L., Mankad S., Sokos G., et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004) 962 s65